These findings suggest that syndrome-specific programs for SA prevention should be considered for individuals with any genetic syndrome with behavioral problems that may increase SA risk
Conclusion GLP-1 maintenance isnt about staying on medication forever, its about protecting the progress youve worked for
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Patients should also be aware that the FDA has issued guidance on compounded semaglutide availability as the supply of brand-name versions has evolved, always verify current regulatory status with your Medvi physician
This represents a critical step toward improving patient outcomes and long-term metabolic health
Despite their promise, GLP-1 drugs need to be treated with caution